Introduction
============

Myocardin was identified as a transcription coactivator of serum response factor in mouse (Wang et al. [@b27]). The human myocardin gene expresses three alternative spliced mRNA variants (Torrado et al. [@b21]) with the longest isoform predominantly found in the heart (Du et al. [@b5]). Myocardin draws intensive interests because it activates the cardiac gene expression and influences heart function. The knockdown of the myocardin gene reduces the expression of cardiac markers in *Xenopus* and chick embryos (Wang et al. [@b27]; Small et al. [@b19]; Chen et al. [@b3]). Myocardin‐deficient adult mouse exhibits early onset of heart failure, dilated cardiomyopathy, and premature death within 1 week (Huang [@b9]) suggesting that myocardin is essential for the development of ventricular cardiomyocytes (Hoofnagle et al. [@b8]). Overexpression of myocardin induced the expression of various cardiac‐specific markers, such as cardiac troponin T (cTnT), MLC2a, MLC2v, *α*‐MHC, *β*‐MHC, GATA4, and sarco/endoplasmic reticulum Ca^2+^‐ATPase 2a (SERCA2a) in human bone marrow (BM)‐mesenchymal stem cells (MSCs) (van Tuyn et al. [@b23]). In addition, myocardin regulates the expression of multiple smooth muscle cell (SMC) differentiation‐related genes, including the smooth muscle (SM) *α*‐actin, SM22*α*, and SM‐calponin (Du et al. [@b5]; van Tuyn [@b22]; Wang and Wang [@b25]; Yoshida et al. [@b30]; van Tuyn et al. [@b23]).

Furthermore, overexpression of myocardin further improved the therapeutic potential of BM‐MSCs in a mouse model of myocardial infarction (Grauss et al. [@b7]), though the underlying mechanism remains unclear. Our recent studies have suggested that MSCs derived from human‐induced pluripotent stem cells (iPSCs) have more potent proliferative capacity and exhibit better therapeutic efficacy in tissue regeneration than BM‐MSCs (Lian et al. [@b16]). The aim of this study was to elucidate the effects of myocardin overexpression on MSC transdifferentiation, electrophysiological properties, and cellular integration of human iPSC‐MSCs with rat cardiomyocytes by examining the expression of cardiac marker genes and ion channel genes, and measuring their electrical conduction velocity. In order to obtain a thorough examination on the effect of forced myocardin expression, both lentiviral and adenoviral transduction systems were used in this study. To mimic the situation of pulsed overexpression of myocardin at the initial stage of transdifferentation, the non‐integration approach of adenoviral system was used to provide a transient forced expression of myocardin. However, the lentiviral system was used to examine the effects of a sustainable myocardin overexpression via genome integration approach.

Materials and Methods
=====================

Cell culture
------------

Human iPSC‐MSCs were derived from iPSCs (iMR90)‐4 (Lian et al. [@b16]). Human BM‐MSCs were purchased from the Lonza Walkersville, Inc. (Walkersville, MD). The cells were cultured as monolayers in DMEM (Thermo Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 5 ng/mL bFGF (Invitrogen), and 5 ng/mL EGF (Peprotech, Hamburg, Germany).

Quantitative real‐time polymerase chain reactions
-------------------------------------------------

Total RNA was extracted from the human BM‐MSCs, human iPSC‐MSCs, human myocardin‐overexpressing iPSC‐MSCs, GFP‐overexpressing iPSC‐MSCs, or cardiomyocytes derived from the human iPSCs (\[iMR90\]‐4) (Lee et al. [@b11]), and it underwent RT‐PCR with various primers ([Table 1](#tbl01){ref-type="table"}) as detailed in our previous work (Zhang et al. [@b32]).

###### 

Oligonucleotide sequences of primers used for RT‐PCR.

  Gene name                       Accession no.   Forward primer (5′--3′)    Reverse primer (5′--3′)    Product size (bp)
  ------------------------------- --------------- -------------------------- -------------------------- -------------------
  Myocardin                       NM_001146312    TTCAGAGGTAACACAGCCTCC      TGATCCTCTCTAGCGTCTGCT      132
  GAPDH                           NM_002046       CCATCTTCCAGGAGCGAG         GCAGGAGGCATTGCTGAT         233
  SERCA2*α*                       NM_001110140    AAGCTATGGGAGTGGTGGTG       GCAATGCAAATGAGGGAGAT       138
  *α*‐MHC                         GI 191623       GATGCCCAGATGGCTGACTT       GGTCAGCATGGCCATGTCCT       275
  *β*‐MHC                         NM_080728.2     GCCAACACCAACCTGTCCAAGTTC   TGCAAAGGCTCCAGGTCTGAGGGC   203
  cTnT                            NM_000364       AGCATCTATAACTTGGAGGCAGAG   TGGAGACTTTCTGGTTATCGTTG    112
  GATA4                           NM_008092       TCTCCCAGGAACATCAAAACC      GTGTGAAGGGGTGAAAAGG        125
  Mef2c                           NM_001131005    ATCTGCCCTCAGTCAGTTGG       AGAAGGCAGGGAGAGATTTGA      73
  Mlc2v                           NM_010861       GACCCAGATCCAGGAGTTCA       AATTGGACCTGGAGCCTCTT       163
  Cx40                            NM_005266       CTGGGCTGGAAGAAGATCAG       TGTGCAGCTCTGGACTATGC       102
  Cx43                            NM_000165       ATGAGCAGTCTGCCTTTCGT       TCTGCTTCAAGTGCATGTCC       249
  Cx45                            NM_005497       AGCAGACAAGAAGGCAGCTC       TTAGGTTTGGGTTGGCTCTG       165
  SM22                            AB209555        AACAGCCTGTACCCTGATGG       CGGTAGTGCCCATCATTCTT       239
  MYH11                           NM_001040113    GGAGGATGAGATCCTGGTCA       TTAGCCGCACTTCCAGTTCT       182
  KCNH1 (a.k.a. EAG1 or Kv10.1)   NM_172362       TGGATTTTGCAAGCTGTCTG       GAGTCTTTGGTGCCTCTTGC       476
  Clcn3                           NM_173872       CATAGGTCAAGCAGAGGGTC       TATTTCCGCAGCAACAGG         293
  KCa1.1                          U11058          ACAACATCTCCCCCAACC         TCATCACCTTCTTTCCAATTC      310
  KCa3.1                          NM_002250       CGGGAACAAGTGAACTCCAT       ACTGGGGAAAGTAGCCTGGT       239
  CACNA1C                         NM_199460       AACATCAACAACGCCAACAA       AGGGCAGGACTGTCTTCTGA       574
  Kir2.1                          NM_000891       AACAGGGAGGTGTGGACAAG       TAACCTGCTCTAGGGCTCCA       261
  Kir2.2                          NM_021012       GAGGCTATCACAGGCTCAGG       CCCCAAGTTAAAAACCAGCA       183
  Kir2.3                          NM_152868       GCTTTGAGCCTGTGGTCTTC       TTGGCTCTGTCCTGAGTGTG       480
  Kv1.4                           NM_002233       ACGAGGGCTTTGTGAGAGAA       CACGATGAAGAAGGGGTCAT       308
  Kv4.2                           NM_012281       GCTTGTCATCAATCCCCTTG       TCCAGTATCTGGGCTTTTCC       102
  Kv4.3                           NM_172198       ACGGAGACATGGTGCCTAAG       CCCTGCGTTTATCAGCTCTC       153
  SCN9A                           NM_002977       GCTCCGAGTCTTCAAGTTGG       GGTTGTTTGCATCAGGGTCT       446

Electrophysiology
-----------------

The expression of ion channels in iPSC‐MSC~LV~^myo^ and iPSC‐MSC~LV~^GFP^ was examined by patch clamp techniques as detailed in our previous work (Zhang et al. [@b32]). In brief, the trypsinized cells were first seeded onto the glass coverslips in a four‐well plate. After a 30--45 min recovery period in the incubator, the cells were transferred into Tyrode\'s solution for patch clamp experiments. Using a HEKA EPC‐10 patch clamp amplifier and the PULSE v8.77 software (HEKA Instruments Inc., Southboro, MA), standard whole‐cell patch clamp recordings were performed at room temperature. The action potentials were recorded under the current (C)‐clamp at 37°C. Then, 1.5 mm thin‐walled borosilicate glass tubing (1.2 mm outer diameter, 0.69 mm internal diameter) (Sutter Instrument Co., Novato, CA) were used to prepare pipettes using a P‐97 Flaming/Brown micropipette puller (Sutter Instrument Co. Novato, CA). The typical pipette resistances were 3--4 MΩ when filled with internal pipette solution. After membrane rupture, the resting membrane potential was recorded under C‐clamp without a current input. The recorded membrane potentials were corrected for a liquid junction potential of +15.6 mV under room temperature, and +15.9 mV under 37°C. During the action potential recordings, the cells were held at 0 pA with 0.1--1 nA stimulation for 5 msec to elicit a response.

Adenovirus preparation
----------------------

The human myocardin gene (NM_001146312.1) was first amplified via PCR from human cardiac cDNA and ligated into the pCR2.1‐TOPO shuttle vector (Invitrogen, Carlsbad, CA). The ORF was subsequently subcloned into pAD‐shuttle‐IRES‐GFP (Stratagene, La Jolla, CA) for adenovirus production. Myocardin‐ and GFP‐expressing adenoviruses were produced using the AdEasy™ XL Adenoviral Vector System (Stratagene, La Jolla, CA). The generated adenoviruses were purified using an Adeno Mini Purification ViraKit (Virapur LLC, SD, CA) before iPSC‐MSCs transduction.

Lentivirus production and transduction
--------------------------------------

Myocardin or GFP gene was inserted into lentivirus expression vector pSIN‐EF2‐Pur (Addgene, MA), and cotransfected with pCMV‐dR8.91 and pMD2G plasmid into 293FT cells (Invitrogen, Carlsbad, CA) using Lipofectamine 2000. Lentivirus were collected 3 days post transfection, filtered (0.45 *μ*m), and used to transduce iPSC‐MSCs with polybrene (Millipore, Billerica, MA). The positively transduced cells were selected using 0.5 *μ*g/mL puromycin‐containing medium after 3 days post transduction.

Immunofluorescence staining
---------------------------

Cells seeded onto glass coverslips were washed with PBS, and fixed with 2% formalin for 30 min at room temperature. The cells were then incubated overnight with primary antibodies (1:200 dilutions in PBS) at 4°C. The primary antibodies included goat polyclonal anti‐myocardin (Santa Cruz Biotechnology Inc., Santa Cruz, CA), mouse antihuman CD29 (Stemgent, San Diego, CA), mouse monoclonal anti‐*α*‐actinin (sarcomeric) (Sigma‐Aldrich, Inc., St. Louis, MO), mouse anti‐myosin heavy chain (cardiac) (Upstate Biotechnology Inc., Waltham, MA), mouse monoclonal antihuman *α*‐actin (smooth muscle) (Dako, Copenhagen, Denmark), mouse monoclonal anti‐troponin T (cardiac) (Thermo Scientific), and rabbit monoclonal anti‐calponin‐1 (Millipore, Billerica, MA). After washing twice with PBS, the cells were incubated with the secondary antibodies for 30 min at 4°C. The secondary antibodies consisted of Alexa‐594 labeled rabbit anti‐goat IgG and Alexa‐647 labeled rabbit anti‐mouse IgG or Alexa‐594 labeled donkey anti‐goat IgG and Alexa‐647 labeled donkey anti‐rabbit IgG for myocardin and calponin costaining. After washing twice, the cells were mounted onto glass slides with mounting medium containing 4′,6‐diamidino‐2‐phenylindole dihydrochloride (DAPI) (Invitrogen). Immunocomplex was examined by fluorescent microscopy (Olympus IX81). To facilitate overlaying multicolored imaging, Alexa 647 was switched to a virtual color of green (512 nm) using Xcellence Pro version 1.1 software.

Neonatal rat cardiomyocytes isolation and multielectrode arrays recording
-------------------------------------------------------------------------

In order to obtain viable cardiomyocyte to assess the electric conductance of the iPSC‐MSCs, cardiomyocyte were isolated from neonatal rat hearts. The animal study protocol conforms to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health and was approved by the ethics committee of the University of Hong Kong (1851‐09). Hearts of neonatal Sprague‐Dawley rats (0--2 days old) were dissected and rinsed with modified Hanks\' balanced salt solution (Invitrogen, Carlsbad, CA) (supplemented with 0.81 mmol/L MgSO~4~, 20 mmol/L HEPES, 100 U/mL penicillin and 100 *μ*g/mL streptomycin, pH = 7.5 by NaOH). The ventricles were minced on ice and dissociated with 0.2% Trypsin 250 (BD Biosciences, San Jose, CA). The dissociated cells were centrifuged down and resuspended in prewarmed neonatal rat ventricular cardiomyocytes (NRVM) culture medium containing DMEM supplemented with 5% FBS, 100 U/mL penicillin, 100 *μ*g/mL streptomycin, 1.5 mmol/L vitamin B~12~ (Sigma‐Aldrich), 10 mg/mL insulin (Sigma‐Aldrich), 10 mg/mL transferrin (Sigma‐Aldrich), and 0.1 mmol/L bromodeoxyuridine (Sigma‐Aldrich). The cells were then filtered (70 *μ*m), and preplated onto a 10‐cm plate for exactly 1 h at 37°C.

The freshly isolated NRVMs were harvested, and mixed with myocardin‐ or GFP‐overexpressing iPSC‐MSCs at a ratio of 4:1, and seeded onto gelatin‐coated multielectrode arrays (MEA) plates (Multi Channel Systems, Reutlingen, Germany) at approximately 10^5^ cells in total. The MEA plates used in this study contained 60 titanium nitride electrodes with a 200 *μ*m interelectrode distance and 30 *μ*m electrode diameter. The MEA plates combined with their supporting hardware allowed the simultaneous recording of extracellular electrical signals from all electrodes with one electrode as the ground. After allowing the NRVMs to settle down overnight, the electrical signals of the cell mixture were recorded and analyzed using the Cardio 2D+ software (Version 1.0.0) (Multi Channel Systems, Reutlingen, Germany).

Statistical analysis
--------------------

The numeric data are presented as mean ± SEM. The statistical significance of the differences between group means was evaluated using analysis of variance (ANOVA) with post hoc Bonferroni test as appropriate. Differences with *P*\<0.05 were considered statistically significant.

Results
=======

Myocardin overexpression in human iPSC‐MSCs via lentivirus and adenovirus‐mediated transfer
-------------------------------------------------------------------------------------------

Positively transduced cells (i.e., iPSC‐MSC~LV~^myo^, iPSC‐MSC~LV~^GFP^, iPSC‐MSC~AD~^myo^, iPSC‐MSC~AD~^GFP^) were verified by RT‐PCR and immunofluorescence staining. As shown in [Figure 1](#fig01){ref-type="fig"}A, the mRNA expression level of myocardin was significantly higher in iPSC‐MSC~LV~^myo^ and iPSC‐MSC~AD~^myo^ than in their corresponding GFP controls. Quantitative RT‐PCR data revealed that the myocardin expression was 125‐ and 45‐fold higher after lentivirus and adenovirus‐mediated transfer, respectively, than the nontransduced cells (Fig. [1](#fig01){ref-type="fig"}B). The myocardin protein was detected in the nucleus of iPSC‐MSC~LV~^myo^ and iPSC‐MSC~AD~^myo^, but not in their GFP controls (Fig. [2](#fig02){ref-type="fig"}). Lentivirus transduced cells were selected with puromycin before further experiments.

![Gene expression analysis of myocardin expressing iPSC‐MSC. (A) Results of RT‐PCR for the detection of cardiomyocyte, smooth muscle cell marker genes, and ion channels genes expression. qPCR data are presented as relative fold change with reference to BM‐MSC. (B) Quantitative real‐time polymerase chain reaction (q‐PCR) gene expression analysis of myocardin expressing iPSC‐MSC. Relative expression cardiomyocyte, smooth muscle cell marker genes, connexins, and ion channels genes expression with reference to iPSC‐MSC are presented. No detectable expression MHC, cTnT, Mlc2V, Kir2.3, Kv1.4, and Kv4.2 were found in iPSC‐MSC. \**P* \< 0.05 versus G~LV~ or G~AD~, respectively.](phy2-2-e00237-g1){#fig01}

![Immunofluorescence staining of myocardin with cardiomyocyte or smooth muscle cell marker genes as depicted in the figure. Adenovirus‐transduced samples were fixed 3 days post transduction, lentivirus transduced cells were fixed 12--14 days post transduction.](phy2-2-e00237-g2){#fig02}

Overexpression of myocardin activated cardiomyocytes and smooth muscle cells marker genes of human iPSC‐MSCs
------------------------------------------------------------------------------------------------------------

The expression of the cardiac marker genes, including *α*‐MHC and GATA4, was observed in myocardin‐transduced human iPSC‐MSCs, although lower than that of the cardiomyocyte control (Fig. [1](#fig01){ref-type="fig"}). The expression level of SERCA, SM22, and connexin43 (Cx43) did not demonstrate obvious changes upon myocardin transduction. Mef2c was significantly upregulated upon myocardin transduction (2.7‐fold) while the expression of connexin40 (Cx40) and connexin45 (Cx45) were downregulated in iPSC‐MSC~LV~^myo^ and iPSC‐MSC~AD~^myo^ (all *P*\<0.05, Fig. [1](#fig01){ref-type="fig"}B). Moreover, there was no detectable expression of cTnT, *β*‐MHC, and MLC2v in iPSC‐MSC~LV~^myo^ and iPSC‐MSC~AD~^myo^. On the other hand, iPSC‐MSC~LV~^myo^ activated the expression of the SMC marker gene MYH11. [Figure 2](#fig02){ref-type="fig"} illustrates the positive staining for calponin, SM *α*‐actin, *α*‐actinin, and cardiac MHC, along with myocardin, in iPSC‐MSC~AD~^myo^ and iPSC‐MSC~LV~^myo^, but not in iPSC‐MSC~AD~^GFP^, iPSC‐MSC~LV~^GFP^, iPSC‐MSCs, or BM‐MSCs.

Overexpression of myocardin‐modulated ion channel profile of human iPSC‐MSCs
----------------------------------------------------------------------------

According to the RT‐PCR results (Fig. [1](#fig01){ref-type="fig"}), the expression of Kv4.3 (responsible for I~to~) (2.2‐fold), SCN9A (for I~Na.TTX~) (1.9‐fold), and CACNA1C (for I~Ca.L~) (3.9‐fold) were upregulated, whereas the expression of KCNH1 (for IK~DR~) (2.5‐fold), KCa3.1 (for IK~Ca~) (9.9‐fold), Kir2.1 and Kir2.2 (for I~Kir~) (3.1‐ and 13.1‐fold, respectively) were downregulated in iPSC‐MSC~LV~^myo^ compared with that in iPSC‐MSC~LV~^GFP^(all *P*\<0.05). No significant difference in the expression of Clcn3 (for I~Cl~) was observed between iPSC‐MSC~LV~^myo^ and iPSC‐MSC~LV~^GFP^.

The functional expression of the ion channels was then further examined by patch clamp in iPSC‐MSC~LV~^myo^ (*n* = 282) and iPSC‐MSC~LV~^GFP^ (*n* = 101). Lentivirus‐mediated transduction combined with puromycin selection was adopted to ensure the successful transduction of myocardin or GFP in each cell for patch clamp. A current, likely I~Cl~ (Tao et al. [@b20]), was recorded in 26% of iPSC‐MSC~LV~^myo^ (72 of 282) and 3% of iPSC‐MSC~LV~^GFP^ (3 of 101) as shown in [Figure 3](#fig03){ref-type="fig"}. The identity of I~Cl~ was confirmed using a chloride channel blocker DIDS. The current was inhibited by DIDS (150 *μ*mol/L) in a representative iPSC‐MSC~LV~^myo^ (Fig. [3](#fig03){ref-type="fig"}A) or iPSC‐MSC~LV~^GFP^ (Fig. [3](#fig03){ref-type="fig"}B). [Figure 3](#fig03){ref-type="fig"}A lower panel illustrates the I--V relationship curve of the DIDS‐sensitive current in iPSC‐MSC~LV~^myo^ (*n* = 7), by subtracting currents recorded after DIDS administration from the control current accordingly.

![I~Cl~ in iPSC‐MSC~LV~^myo^ and iPSC‐MSC~LV~^GFP^. Voltage‐dependent current was inhibited by the Cl^−^ channel blocker DIDS (150 *μ*mol/L) in a representative iPSC‐MSC~LV~^myo^ (A) or iPSC‐MSC~LV~^GFP^ (B). Current was elicited by the protocol shown in the inset. I--V relationship of DIDS‐sensitive current obtained by subtracting the currents recorded before and after DIDS application in iPSC‐MSC~LV~^myo^ (*n* = 7) (A, lower panel)**.**](phy2-2-e00237-g3){#fig03}

This inward component exhibited properties similar to I~Kir~ (Deng et al. [@b4]) were observed in both iPSC‐MSC~LV~^myo^ (9%, 18 of 282) and iPSC‐MSC~LV~^GFP^ (12%, 11 of 101). The existence of I~Kir~ was determined using 0.5 mmol/L Ba^2+^, a specific blocker for I~Kir~. As displayed in [Figure 4](#fig04){ref-type="fig"}A and B, the inward rectifying K^+^ current was reversibly suppressed by 0.5 mmol/L BaCl~2~ in both iPSC‐MSC~LV~^myo^ and iPSC‐MSC~LV~^GFP^. The I--V relationships of I~Kir~, elicited with a 1.2 sec ramp protocol (from −120 to 0 mV) in a solution containing 5 mmol/L K^+^ (Tyrode\'s solution) or 20 mmol/L K^+^, and after application of 0.5 mmol/L Ba^2+^ in the bath solution are illustrated in a representative iPSC‐MSC~LV~^myo^ (Fig. [4](#fig04){ref-type="fig"}A, lower panel) or iPSC‐MSC~LV~^GFP^ (Fig. [4](#fig04){ref-type="fig"}B, lower panel). Similar results were observed in 12 iPSC‐MSC~LV~^myo^ and 4 iPSC‐MSC~LV~^GFP^.

![I~Kir~ in iPSC‐MSC~LV~^myo^ and iPSC‐MSC~LV~^GFP^. Voltage‐dependent currents, elicited with the inset protocol, were reversibly inhibited by BaCl~2~ (0.5 mmol/L) in a representative iPSC‐MSC~LV~^myo^ (A) or iPSC‐MSC~LV~^GFP^ (B), or with a 1.2‐sec ramp protocol (−120 to 0 mV from a holding potential of −40 mV) in another representative iPSC‐MSC~LV~^myo^ (A, lower panel) or iPSC‐MSC~LV~^GFP^ (B, lower panel) in the presence of 5 mmol/L K~o~^+^, 20 mmol/L K~o~^+^, or 0.5 mmol/L Ba^2+^ in bath solution.](phy2-2-e00237-g4){#fig04}

An outward current, likely BK~Ca~ current (Li et al. [@b14]), was activated in both iPSC‐MSC~LV~^myo^ (68%, 191 of 282) and iPSC‐MSC~LV~^GFP^ (85%, 86 of 101) as shown in [Figure 5](#fig05){ref-type="fig"}A and B. The identity of BK~Ca~ was confirmed using the BK~Ca~ channel‐specific blocker paxilline (Fig. [5](#fig05){ref-type="fig"}A and B). After administration of paxilline, the current activated at +60 mV, was significantly reduced from 2.9 ± 0.4 pA/pF to 1.0 ± 0.12 pA/pF in iPSC‐MSC~LV~^myo^ (*n* = 11, *P*\<0.001), and from 28.6 ± 8.4 pA/pF to 8.6 ± 1.9 pA/pF in iPSC‐MSC~LV~^GFP^ (*n* = 9, *P*\<0.05).

![BK~Ca~ in iPSC‐MSC~LV~^myo^, BK~Ca~, IK~DR~, and IK~Ca~ in iPSC‐MSC~LV~^GFP^. Noisy currents were completely inhibited by paxilline (1 *μ*mol/L) in a representative iPSC‐MSC~LV~^myo^ (A) or iPSC‐MSC~LV~^GFP^ (B). I--V relationship of paxilline‐sensitive currents obtained by subtracting the currents before and after paxilline treatment accordingly in iPSC‐MSC~LV~^myo^ (*n* = 12) (A, right panel) and iPSC‐MSC~LV~^GFP^ (*n* = 5) (B, right panel). Voltage‐dependent currents in a representative iPSC‐MSC~LV~^GFP^ were partially inhibited by paxilline (1 *μ*mol/L) and completely abolished by 4‐AP (5 mmol/L) (*n* = 5) (C) or clotrimazole (1 *μ*mol/L) (*n* = 3) (D). Currents were elicited by the protocol shown in the inset.](phy2-2-e00237-g5){#fig05}

Two types of paxilline‐resistant currents were recorded in iPSC‐MSC~LV~^GFP^ but not in iPSC‐MSC~LV~^myo^. As shown in [Figure 5](#fig05){ref-type="fig"}C, a paxilline‐resistant current in a representative iPSC‐MSC~LV~^GFP^ was further inhibited by IK~DR~ blocker 4‐AP. Paxilline (1 *μ*mol/L) partially suppressed the membrane current at +60 mV from 19.2 ± 3.7 pA/pF to 9.2 ± 2.4 pA/pF. The remaining current was inhibited by 4‐AP (5 mmol/L) to 2.2 ± 1.5 pA/pF (*n* = 5, *P*\<0.05). The other type of current displayed properties of IK~Ca~ (Tao et al. [@b20]) was detected only in iPSC‐MSC~LV~^GFP^ (6%, 6 of 101). In [Figure 5](#fig05){ref-type="fig"}D, the outward current in a representative iPSC‐MSC~LV~^GFP^ was partially inhibited by paxilline (1 *μ*mol/L), with the remaining current completely blocked by the IK~Ca~ blocker clotrimazole (1 *μ*mol/L). Similar results were observed in five iPSC‐MSC~LV~^GFP^ cells.

Two other types of currents were recorded in iPSC‐MSC~LV~^myo^ but not in iPSC‐MSC~LV~^GFP^. One was the transient outward K^+^ current I~to~ sensitive to 4‐AP (Li et al. [@b14]). I~to~ was detected in a small portion of iPSC‐MSC~LV~^myo^ (4%, 11 of 282) with a representative one shown in [Figure 6](#fig06){ref-type="fig"}A. The voltage‐dependent inactivation of I~to~ was assessed by the step potential at +50 mV after 1000 ms conditioning potentials from −110 to 0 mV (Fig. [6](#fig06){ref-type="fig"}B). The I~to~ inactivation curve was obtained by plotting I/I~max~ of I~to~ (the peak value of I~to~ normalized to the maximum one) as a function of the conditioning potentials and fitting to the Boltzmann sigmoidal curve. The slope of the I~to~ inactivation curve was approximately 9.3 ± 1.7, and the half inactivated conditioning potential was approximately −64.0 ± 1.9 mV (*n* = 6). The time‐dependent recovery of I~to~ from inactivation was estimated with a paired‐pulse protocol (shown in the inset of Fig. [6](#fig06){ref-type="fig"}C). The I~to~ recovery curve was fit to an exponential function‐one phase association with the time constant (*ζ*) 61.5 msec and half‐time 42.6 msec (*n* = 4).

![I~to~, and I~Na.TTX~ in iPSC‐MSC~LV~^myo^. (A) I~to~ currents in a representative iPSC‐MSC~LV~^myo^ were inhibited by 4‐AP (5 mmol/L). (B) Voltage‐dependent inactivation of I~to~ in a representative cell and normalized mean values (I/I~max~) under different voltages (*n* = 6). (C) The recovery curve of I~to~. P2 current was normalized by P1 current and plotted against the P1‐P2 interval (*n* = 5). (D) An inward current (arrow) recorded in a representative cell was reversibly inhibited by TTX (100 nmol/L) (*n* = 4). Currents were elicited by the protocol shown in the inset.](phy2-2-e00237-g6){#fig06}

The other current exclusively observed in iPSC‐MSC~LV~^myo^ was an inward current activated from approximately −30 to +60 mV and sensitive to tetrodotoxin (TTX). This phenomenon suggested the existence of I~Na.TTX~ (Li et al. [@b14]) in iPSC‐MSC~LV~^myo^ (4%, 12 of 282). [Figure 6](#fig06){ref-type="fig"}D demonstrates that TTX (100 nmol/L) reversibly inhibited the inward current, with limited effects on the outward current. Similar results were observed in four iPSC‐MSC~LV~^myo^ cells.

In summary, a similar functional ion channel profile (i.e., BK~Ca~, I~Kir~, I~Cl~, IK~DR~, and IK~Ca~) as in iPSC‐MSCs (Zhang et al. [@b32]) was observed in iPSC‐MSC~LV~^GFP^ (85%, 12%, 3%, 56%, and 6%). Two distinct ion channels, I~to~ and I~Na.TTX~ were recorded in iPSC‐MSC~LV~^myo^ (68%, 9%, 26%, 4%, and 4%).

Furthermore, iPSC‐MSC~LV~^myo^ had a RMP of −25.9 ± 0.7 mV, which was more depolarizing than that of iPSC‐MSC~LV~^GFP^ (−32.1 ± 1.6 mV) (*P*\<0.001). In addition, the cell size of iPSC‐MSC~LV~^myo^ was significantly increased upon myocardin transduction than iPSC‐MSC~LV~^GFP^ (*P*\<0.001), as reflected by their respective average membrane capacitance (69.3 ± 2.5 pF vs. 22.4 ± 1.7 pF).

Myocardin overexpressed iPSC‐MSCs did not exhibit action potentials as mature cardiomyocytes
--------------------------------------------------------------------------------------------

To assess whether overexpression of myocardin resulted in complete cardiomyocyte differentiation of iPSC‐MSCs, the action potential of iPSC‐MSC~LV~^myo^, iPSC‐MSC~LV~^myo^ incubated in cardiomyocyte differentiation medium, iPSC‐MSC~AD~^myo^, and their GFP controls (*n* = 11--23) were also characterized (Fig. [7](#fig07){ref-type="fig"}). However, none of these cells exhibited action potentials as mature cardiomyocytes.

![Action potentials in myocardin or GFP transduced iPSC‐MSCs. Action potentials shown in a representative human iPSC‐MSC~AD~^myo^ (A), iPSC‐MSC~AD~^GFP^ (B), iPSC‐MSC~LV~^myo^ (C), iPSC‐MSC~LV~^GFP^ (D), iPSC‐MSC~LV~^myo^ incubated in cardiomyocyte (CM) differentiation medium for 5 days (E) or its GFP control (F).](phy2-2-e00237-g7){#fig07}

Overexpression of myocardin significantly increased the electrical conduction velocity of human iPSC‐MSCs
---------------------------------------------------------------------------------------------------------

The effects of myocardin overexpression on the cellular integration and conductance changes of iPSC‐MSC with cardiomyocytes were determined by measuring the electrical conduction velocity in a monolayer coculture of iPSC‐MSC~AD~^myo^ or iPSC‐MSC~AD~^GFP^ with NRVMs on MEA recording plates (Fig. [8](#fig08){ref-type="fig"}A). The electrical signals transmitted through the MEA plate were recorded as shown in a representative iPSC‐MSC~AD~^GFP^ (Fig. [8](#fig08){ref-type="fig"}B) or iPSC‐MSC~AD~^myo^ (Fig. [8](#fig08){ref-type="fig"}C), coculture system. The electrical conduction velocities of iPSC‐MSC~AD~^myo^ (*n* = 13; 0.13 ± 0.03 m/sec) were significantly faster than those of iPSC‐MSC~AD~^GFP^ (*n* = 15; 0.07 ± 0.01 m/sec) (Fig. [8](#fig08){ref-type="fig"}D, *P* \< 0.05).

![Cocultures of NRVMs and iPSC‐MSC. (A) NRVMs were cocultured with iPSC‐MSC~AD~^GFP^ on a MEA recording plate. The electrical signals transmitted through MEA plate were recorded in NRVMs cocultured with 20% iPSC‐MSC~AD~^GFP^ (B), or iPSC‐MSC~AD~^myo^ (C), with the average conduction velocity of 0.07 ± 0.01 m/sec and 0.13 ± 0.03 m/sec, respectively (D). \**P* \< 0.05.](phy2-2-e00237-g8){#fig08}

Discussion
==========

Recent clinical studies have suggested that MSC is a potential cell source for cardiac regeneration in patients with myocardial infarction and heart failure (Siu and Tse [@b18]). The underlying mechanisms of the beneficial effect of MSC for cardiac regeneration likely mediated through multiple actions, including transdifferentiation into functional cardiomyocyte or fusion with native cardiomyocytes, paracrine effects, cell‐cell interactions, and integration with native cardiomyocytes (Williams and Hare [@b28]). Previous studies have shown that myocardin activates cardiac gene expression in BM‐MSCs (van Tuyn et al. [@b23]), and improved their therapeutic potential for myocardial infarction (Grauss et al. [@b7]).

This study is the first to investigate the effect of myocardin overexpression in human iPSC‐MSCs. Our previous studies have shown that iPSC‐MSCs exhibit higher proliferative potential and better therapeutic efficacy for tissue regeneration (Lian et al. [@b16]; Zhang et al. [@b32]). In this study, the myocardin overexpression in human iPSC‐MSCs resulted in partial transdifferentiation into cardiomyocyte phenotypes as reflected by the appearance of cardiac markers *α*‐MHC, GATA4, *α*‐actinin, and cardiac MHC, but not cardiac markers cTnT, *β*‐MHC, MLC2v, and cTnT protein. These findings were consistent with those observed in myocardin overexpression in BM‐MSC (van Tuyn et al. [@b23]; Grauss et al. [@b7]). Therefore, myocardin overexpression alone could not induce complete cardiomyocyte transdifferentiation from iPSC‐MSCs as observed in BM‐MSC. The incomplete transdifferentiation into mature cardiomyocyte phenotypes from myocardin‐transduced iPSC‐MSCs was further confirmed by the lack of mature action potentials recorded by patch clamping (data not shown). It is likely that those phenotypic changes of the MSC are due to secondary effect of multiple genes expression induced by myocardin rather than direct myocardin transcriptional activity to induce complete cardiac transdifferentiation. Moreover, our findings reveal several similar as well as different gene expression profiles related transient versus long‐term expression of myocardin using adenovirus and lentivirus transduction, respectively.

In this study, we characterized and compared the ion channel profiles of iPSC‐MSC~LV~^myo^ and iPSC‐MSC~LV~^GFP^ to assess the electrophysiological effects of myocardin overexpression on iPSC‐MSCs. RT‐PCR results revealed that iPSC‐MSC~LV~^myo^ has higher expression levels of Kv4.3 (responsible for I~to~), KCa1.1 (for BK~Ca~), SCN9A (for I~Na.TTX~), and CACNA1C (for I~Ca.L~), but lower expression levels of KCa3.1 (for IK~Ca~), KCNH1 (for IK~DR~), and Kir2.1 and Kir2.1 (for I~Kir~) than those of iPSC‐MSC~LV~^GFP^. Both iPSC‐MSC~LV~^myo^ and iPSC‐MSC~LV~^GFP^ had similar expression levels of Clcn3 (for I~Cl~). Patch clamp results showed that BK~Ca~, I~Kir~, I~Cl~, I~to~, and I~Na.TTX~ were expressed in iPSC‐MSC~LV~^myo^ (68%, 9%, 26%, 4%, and 4%), compared with BK~Ca~, I~Kir~, I~Cl~, IK~DR~ and IK~Ca~ in iPSC‐MSC~LV~^GFP^ (85%, 12%, 3%, 56%, and 6%). Overexpression of myocardin upregulated the functional expression of I~Cl~ channels and activated the functional expression of I~to~ and I~Na.TTX~ channels, but inhibited the functional expression of the IK~Ca~ IK~DR~ and I~Kir~ channels.

The expression of the human Clcn3 gene is mainly found in the skeletal muscle and brain (Borsani et al. [@b2]). The inactivation of the Clcn3 gene causes severe myocardial hypertrophy and heart failure in knockout mice (Xiong et al. [@b29]). Clcn3 encodes the I~Cl~ channel, which is volume‐sensitive and can be activated under hypotonic conditions, as shown in human gastric epithelial cells (Jin et al. [@b10]), mouse BM‐MSCs (Tao et al. [@b20]), and bovine epithelial cells (Wang et al. [@b26]). In this study, the size of the iPSC‐MSC~LV~^myo^ greatly expanded compared with iPSC‐MSC~LV~^GFP^, as reflected by the increase in the average membrane capacitance from 22.4 ± 1.7 pF to 69.3 ± 2.5 pF. The percentage of cells that displayed I~Cl~ currents increased from 3% to 26%. The activation of the volume‐sensitive I~Cl~ channel possibly resulted from the increase in the cell volume of iPSC‐MSC~LV~^myo^.

The I~to~ channel is encoded by Kv1.4, Kv4.2, and Kv4.3, which have been detected in the human heart (Gaborit et al. [@b6]). In this study, the expression of Kv4.3, but not Kv1.4 and Kv4.2, was found in iPSC‐MSC~LV~^myo^. Therefore, the I~to~ current recorded in iPSC‐MSC~LV~^myo^ is likely mediated by the expression of Kv4.3. The I~to~ current is one of the critical components of the action potential in mature ventricular cardiomyocytes (Amin et al. [@b1]). 4‐AP sensitive I~to~ current has been observed in atrial and ventricular cardiomyocytes (Li et al. [@b12], [@b13]). In this study, I~to~ current has been detected in only 4% of iPSC‐MSC~LV~^myo^. These results suggest that overexpression of myocardin directs the transdifferentiation of iPSC‐MSCs to cardiomyocyte phenotypes, although at a very low efficiency.

In addition, myocardin can activate the expression of SMC marker genes in mouse ESCs (Du et al. [@b5]), fibroblast (Wang and Wang [@b25]), human BM‐MSCs and fibroblast (van Tuyn et al. [@b23]), and human ventricular scar fibroblast (van Tuyn [@b22]). In this study, myocardin induced the expression of SMC marker genes (i.e., SM22, MYH11, calponin, and SM *α*‐actin) in the iPSC‐MSCs. However, myocardin expression did not induce complete SMC transdifferentiation (Yoshida et al. [@b31]). Although the potential role of SMC transdifferentiation remains unclear, MSC‐derived SMC might enhance vasculogenesis.

The expression of SCN9A mRNA is significantly upregulated in iPSC‐MSC~LV~^myo^ compared with that in iPSC‐MSC~LV~^GFP^ or non‐transduced cells. SCN9A might be responsible for the I~Na.TTX~ current recorded in iPSC‐MSC~LV~^myo^ (4%). The I~Na.TTX~ current has been observed in the human BM‐MSCs (Li et al. [@b14]) and cardiac fibroblasts (Li et al. [@b15]). However, no TTX‐resistant sodium current encoded by SCN5A has been recorded in the iPSC‐MSC~LV~^myo^. The expression level of SCN5A is much higher than that of SCN9A in the human heart (Gaborit et al. [@b6]). Furthermore, other important ion currents, such as I~Ca.L~and I~f~ that compose the action potential of cardiomyocytes (Amin et al. [@b1]) have not been detected in iPSC‐MSC~LV~^myo^. These data again suggest that myocardin induces incomplete cardiomyocyte transdifferentiation from iPSC‐MSCs.

In addition to the induction of the functional expression of the I~to~ and I~Na.TTX~ channels, forced myocardin expression interferes with the expression of the IK~Ca~ and the ether à go‐go 1 potassium (responsible for IK~DR~) channels. The occurrence of the IK~Ca~ current (possibly encoded by the KCa3.1) in iPSC‐MSC~LV~^GFP^ is approximately 6%, which is comparable with those in iPSC‐MSCs (5%, (Zhang et al. [@b32])). The absence of the IK~Ca~ current in iPSC‐MSC~LV~^myo^ might have resulted from the decreased expression of KCa3.1. As we have shown previously, the ether à go‐go 1 potassium channel is critical in the regulation of the proliferation of iPSC‐MSCs (Zhang et al. [@b32]). The proliferation of iPSC‐MSC~LV~^myo^ has been greatly suppressed (data not shown). Myocardin possibly downregulates the expression of the ether à go‐go 1 potassium channel and thus inhibits the proliferation of iPSC‐MSC~LV~^myo^.

With a conduction gap in an NRVM‐seeded MEA plate filled with desired cells, Pijnappels et al. ([@b17]) measured the conduction velocities of BM‐MSCs and NRVMs to be 0.014 ± 0.004 m/sec and 0.168 ± 0.002 m/sec, respectively. Moreover, they have demonstrated that the electrical conduction of BM‐MSCs is caused by the expression of Cx43. Subsequently, they further showed that the forced myocardin expression induces the human ventricular scar fibroblasts to repair the conduction block of the NRVM field, possibly mediated by the upregulation of the expression of Cx40 and Cx45 (van Tuyn [@b22]). In contrast to these observations, our results showed that Cx40 and Cx45 expression, but not Cx43 were reduced upon myocardin transduction. While Cx40 and Cx45 are expressed in the embryonic heart, their expressions in the adult heart are mainly localized to pacemaker and conduction system. On the other hand, Cx43 is abundantly expressed in the myocardium. Therefore, downregulation of Cx40 and Cx45 after myocardin transduction may represent a transdifferentiation to a more mature ventricular phenotype (Verheule and Kaese [@b24]). Nevertheless, the conduction velocity of NRVMs cocultured iPSC‐MSC~AD~^myo^ was significantly faster than that of their GFP counterparts. Therefore, forced myocardin expression increased conduction velocity possibly because of its effects on the ion channel expression of iPSC‐MSCs rather than changes in connexins expression, in particular, by activating the expression of INa. TTX. Moreover, this increase in conduction velocity might account for the superior therapeutic potential of myocardin transduced BM‐MSCs than that of BM‐MSCs themselves in the mouse model of myocardial infarction (Grauss et al. [@b7]). These results suggest that similar to BM‐MSCs, iPSC‐MSCs are capable of conducting the electrical signals from NRVMs. More importantly, forced myocardin expression enhances the electrical conduction of iPSC‐MSCs.

The forced myocardin expression in human iPSC‐MSCs lead to partial transdifferentiation into cardiomyocytes and SMC phenotypes, modified the expression profile of the ion channels, and improved the electrical conduction velocity during coculturing with NRVM. The changes in the electrophysiological properties of iPSC‐MSC can potentially improve their electrical coupling with native cardiomyocytes after transplantation, thus reducing the risk of proarrhythymias. However, the therapeutic effect of the ectopic expression of myocardin in iPSC‐MSCs for cardiac repair and regeneration warrants further investigation in in vivo animal models of cardiac injuries such as myocardial infarction.
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